NE BUSINESS BUREAU
AHMEDABAD, SEP 24
City-based drug firm Cadila Healthcare on Friday said it has entered into an agreement with Shilpa Medicare for the production of its COVID-19 vaccine, ZyCoV-D.
The company has, “entered into a definitive agreement with Shilpa Medicare, via its wholly owned subsidiary, Shilpa Biologicals for production-supply of the ZyCoV-D vaccine drug substance from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka,” Cadila Healthcare said in a regulatory filing.
The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties, it added.
“The company will transfer the ZyCoV-D technology to Shilpa Biologicals Pvt Ltd (SBPL). Under the agreement, SBPL will be responsible for manufacture of the drug substance of the vaccine, while the company is responsible for filling / packaging / distribution / marketing of the vaccine in its marketing territories,” Cadila Healthcare said.
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the COVID-19 virus, it added.
The vaccine was granted the Emergency Use Authorisation (EUA) by the Indian drug regulator on August 20.
